![Marek Kwiatkowski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marek Kwiatkowski
Corporate Officer/Principal en QUIAPEG PHARMACEUTICALS HOLDING AB .
Cargos activos de Marek Kwiatkowski
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
QUIAPEG PHARMACEUTICALS HOLDING AB | Corporate Officer/Principal | 01/01/2022 | - |
Director Técnico/Científico/I+D | 01/01/2017 | 01/01/2022 | |
University of Uppsala | Corporate Officer/Principal | - | - |
Otradama & Partners AB | Director/Miembro de la Junta | - | - |
Historial de carrera de Marek Kwiatkowski
Antiguos cargos conocidos de Marek Kwiatkowski.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Quiatech AB
![]() Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Director/Miembro de la Junta | - | 30/08/2007 |
Director Técnico/Científico/I+D | - | 30/08/2007 | |
QuiaPEG Pharmaceuticals AB
![]() QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | 01/01/2012 | - |
Fundador | 01/01/2012 | - | |
OLIGOvation AB
![]() OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Director/Miembro de la Junta | - | - |
Director Técnico/Científico/I+D | - | - |
Formación de Marek Kwiatkowski.
University of Uppsala | Doctorate Degree |
Uniwersytet Jagiellonski | Undergraduate Degree |
Estadísticas
Internacional
Suecia | 7 |
Polonia | 2 |
Operativa
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Empresas privadas | 4 |
---|---|
Quiatech AB
![]() Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
OLIGOvation AB
![]() OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Commercial Services |
QuiaPEG Pharmaceuticals AB
![]() QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
Otradama & Partners AB |
- Bolsa de valores
- Insiders
- Marek Kwiatkowski
- Experiencia